drugset / Trial / NCT00630825

A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus

NCT00630825

Phase 2 Completed 262 enrolled Eli Lilly and Company
RandomizedParallel-groupTriple-blindTreatment

Summary

To study once weekly injections of LY2189265 compared to placebo on blood glucose by measuring glycosylated hemoglobin (HbA1c) change from baseline after 16 weeks in overweight Type 2 Diabetes Mellitus participants.

Timeline

Start
2008-04
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Dulaglutide Peptide 1 mg Subcutaneous
Subject Dulaglutide Peptide 2 mg Subcutaneous